Protalix Biotherapeutics Inc (PLX)

455
+6(+1.25%)
  • Volume:
    15,379
  • Bid/Ask:
    454/456
  • Day's Range:
    449 - 464
  • Type:Equity
  • Market:Israel
  • ISIN:US74365A3095
  • S/N:1120609

PLX Overview

Prev. Close
449
Day's Range
449-464
Revenue
-
Open
450
52 wk Range
421-2,290
EPS
-1.63
Volume
15,379
Market Cap
204.68M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
147,224
P/E Ratio
-
Beta
1.77
1-Year Change
-62.86%
Shares Outstanding
45,556,647
Next Earnings Date
Nov. 10, 2021
What is your sentiment on Protalix Biotherapeutics Inc?
or
Vote to see community's results!

Protalix Biotherapeutics Inc News

Protalix Biotherapeutics Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellSellStrong SellStrong Sell
Technical IndicatorsBuyStrong SellStrong SellStrong SellStrong Sell
SummaryNeutralStrong SellStrong SellStrong SellStrong Sell

Protalix Biotherapeutics Inc Company Profile

Protalix Biotherapeutics Inc Company Profile

Employees
207

Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in Israel, Brazil, rest of Latin America, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is headquartered in Karmiel, Israel.

Read More
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.